# Cryo Cell International Inc: filings

CCEL · NYSE · CIK 862692 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Nov 30

Pages: [Overview](/companies/ccel.md) · [Financials](/companies/ccel/financials.md) · [Filings](/companies/ccel/filings.md) · [Insiders](/companies/ccel/insiders.md)

## Reports and events: 256 filings

Newest first, by EDGAR acceptance time (Eastern). Filter with ?form= one of: `periodic`, `8-K`, `10-K`, `10-Q`, `4`, `proxy`, `13dg`, `all`, or any form this company filed (4 290, 8-K 142, 10-Q 54, 10-K 18, DEF 14A 16, DFAN14A 15, SC 13D/A 15, 3 13, DEFA14A 13, UPLOAD 13, SC 13G/A 9, CORRESP 8, 4/A 5, ARS 4, SC 13G 4, 10-Q/A 3, DEFC14A 3, NT 10-Q 3, PRER14A 3, PRRN14A 3, S-8 3, 8-A12B 2, CERT 2, PREC14A 2, PREN14A 2, SC 13D 2, 10-K/A 1, 25 1, 3/A 1, 8-A12G 1, 8-K/A 1, DEFN14A 1, DEFR14A 1, PRE 14A 1, RW 1, S-1 1, S-1/A 1, SCHEDULE 13D 1, SCHEDULE 13D/A 1, SCHEDULE 13G 1, SC TO-I 1, SC TO-I/A 1).

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-13 | 21:00 ET | [DEF 14A](/filings/0001193125-26-420608.md) | Proxy statement, period 2026-10-27 | 0001193125-26-420608 |
| 2026-10-09 | 20:30 ET | [10-Q](/filings/0001193125-26-419156.md) | Quarterly report, period 2026-08-31 | 0001193125-26-419156 |
| 2026-09-14 | 20:30 ET | [8-K](/filings/0001193125-26-390647.md) | 8.01 Other events | 0001193125-26-390647 |
| 2026-07-15 | 20:30 ET | [10-Q](/filings/0001193125-26-304834.md) | Quarterly report, period 2026-05-31 | 0001193125-26-304834 |
| 2026-07-07 | 13:01 ET | [SCHEDULE 13D/A](/filings/0001493152-26-032265.md) | Ownership report, active investor, amended | 0001493152-26-032265 |
| 2026-05-08 | 20:00 ET | [8-K](/filings/0001193125-26-214569.md) | 3.01 Delisting notice; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-214569 |
| 2026-04-14 | 21:00 ET | [10-Q](/filings/0001193125-26-155057.md) | Quarterly report, period 2026-02-28 | 0001193125-26-155057 |
| 2026-03-25 | 01:54 ET | [SCHEDULE 13D](/filings/0001493152-26-012763.md) | Ownership report, active investor | 0001493152-26-012763 |
| 2026-03-12 | 21:00 ET | [8-K](/filings/0001193125-26-104392.md) | 3.01 Delisting notice; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-104392 |
| 2026-02-27 | 22:01 ET | [10-K](/filings/0001193125-26-083096.md) | Annual report, period 2025-11-30 | 0001193125-26-083096 |
| 2025-11-12 | 22:00 ET | [8-K](/filings/0001193125-25-277872.md) | 8.01 Other events | 0001193125-25-277872 |
| 2025-10-23 | 21:00 ET | [8-K](/filings/0001193125-25-248883.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 9.01 Financial statements and exhibits | 0001193125-25-248883 |
| 2025-10-15 | 21:00 ET | [10-Q](/filings/0001193125-25-240385.md) | Quarterly report, period 2025-08-31 | 0001193125-25-240385 |
| 2025-09-26 | 21:00 ET | [DEF 14A](/filings/0001193125-25-220757.md) | Proxy statement, period 2025-10-21 | 0001193125-25-220757 |
| 2025-09-10 | 21:00 ET | [8-K](/filings/0001193125-25-200170.md) | 8.01 Other events | 0001193125-25-200170 |
| 2025-07-15 | 21:00 ET | [10-Q](/filings/0000950170-25-095916.md) | Quarterly report, period 2025-05-31 | 0000950170-25-095916 |
| 2025-05-22 | 21:00 ET | [8-K](/filings/0000950170-25-076433.md) | 1.02 Termination of a material agreement | 0000950170-25-076433 |
| 2025-05-08 | 21:00 ET | [8-K](/filings/0000950170-25-067147.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0000950170-25-067147 |
| 2025-04-14 | 21:00 ET | [10-Q](/filings/0000950170-25-053767.md) | Quarterly report, period 2025-02-28 | 0000950170-25-053767 |
| 2025-02-28 | 22:00 ET | [10-K](/filings/0000950170-25-030138.md) | Annual report, period 2024-11-30 | 0000950170-25-030138 |
| 2024-10-31 | 21:15 ET | [8-K](/filings/0000950170-24-119642.md) | 5.07 Shareholder vote results | 0000950170-24-119642 |
| 2024-10-30 | 12:45 ET | [8-K](/filings/0000950170-24-118607.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0000950170-24-118607 |
| 2024-10-17 | 21:13 ET | [10-Q/A](/filings/0000950170-24-115377.md) | Quarterly report, amended, period 2024-08-31 | 0000950170-24-115377 |
| 2024-10-17 | 21:54 ET | [8-K](/filings/0000950170-24-115106.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-115106 |
| 2024-10-15 | 21:18 ET | [10-Q](/filings/0000950170-24-114762.md) | Quarterly report, period 2024-08-31 | 0000950170-24-114762 |
| 2024-10-07 | 21:00 ET | [DEF 14A](/filings/0001193125-24-233861.md) | Proxy statement, period 2024-10-29 | 0001193125-24-233861 |
| 2024-09-17 | 21:00 ET | [8-K](/filings/0000950170-24-107340.md) | 8.01 Other events | 0000950170-24-107340 |
| 2024-07-15 | 21:00 ET | [10-Q](/filings/0000950170-24-083637.md) | Quarterly report, period 2024-05-31 | 0000950170-24-083637 |
| 2024-04-15 | 21:10 ET | [10-Q](/filings/0000950170-24-044493.md) | Quarterly report, period 2024-02-29 | 0000950170-24-044493 |
| 2024-03-26 | 12:30 ET | [8-K](/filings/0000950170-24-036165.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000950170-24-036165 |
| 2024-02-28 | 22:20 ET | [10-K](/filings/0000950170-24-022275.md) | Annual report, period 2023-11-30 | 0000950170-24-022275 |
| 2023-10-12 | 21:01 ET | [10-Q](/filings/0000950170-23-053143.md) | Quarterly report, period 2023-08-31 | 0000950170-23-053143 |
| 2023-10-12 | 20:30 ET | [8-K](/filings/0000950170-23-053122.md) | 5.07 Shareholder vote results | 0000950170-23-053122 |
| 2023-09-14 | 20:30 ET | [DEF 14A](/filings/0001193125-23-235338.md) | Proxy statement, period 2023-10-10 | 0001193125-23-235338 |
| 2023-08-25 | 20:17 ET | [8-K](/filings/0001193125-23-221510.md) | 8.01 Other events | 0001193125-23-221510 |
| 2023-07-14 | 21:11 ET | [10-Q](/filings/0000950170-23-033057.md) | Quarterly report, period 2023-05-31 | 0000950170-23-033057 |
| 2023-04-21 | 20:32 ET | [10-Q](/filings/0000950170-23-013868.md) | Quarterly report, period 2023-02-28 | 0000950170-23-013868 |
| 2023-03-09 | 22:09 ET | [8-K](/filings/0000950170-23-007079.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0000950170-23-007079 |
| 2023-02-28 | 22:29 ET | [10-K](/filings/0000950170-23-005220.md) | Annual report, period 2022-11-30 | 0000950170-23-005220 |
| 2022-12-29 | 22:01 ET | [8-K](/filings/0000950170-22-027095.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0000950170-22-027095 |
| 2022-10-18 | 00:31 ET | [10-Q](/filings/0000950170-22-019626.md) | Quarterly report, period 2022-08-31 | 0000950170-22-019626 |
| 2022-10-05 | 21:00 ET | [8-K](/filings/0000950170-22-019317.md) | 5.07 Shareholder vote results | 0000950170-22-019317 |
| 2022-09-16 | 21:01 ET | [DEF 14A](/filings/0001193125-22-246473.md) | Proxy statement, period 2022-10-03 | 0001193125-22-246473 |
| 2022-08-23 | 21:00 ET | [8-K](/filings/0000950170-22-017696.md) | 8.01 Other events | 0000950170-22-017696 |
| 2022-08-23 | 22:02 ET | [8-K](/filings/0000950170-22-017659.md) | 8.01 Other events | 0000950170-22-017659 |
| 2022-07-22 | 20:31 ET | [8-K](/filings/0000950170-22-012926.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation | 0000950170-22-012926 |
| 2022-07-11 | 21:01 ET | [10-Q](/filings/0000950170-22-012605.md) | Quarterly report, period 2022-05-31 | 0000950170-22-012605 |
| 2022-04-28 | 00:37 ET | [S-1/A](/filings/0001193125-22-124542.md) | Registration statement, amended | 0001193125-22-124542 |
| 2022-04-27 | 13:20 ET | [10-Q/A](/filings/0000950170-22-006286.md) | Quarterly report, amended, period 2022-02-28 | 0000950170-22-006286 |
| 2022-04-13 | 20:31 ET | [10-Q](/filings/0000950170-22-005662.md) | Quarterly report, period 2022-02-28 | 0000950170-22-005662 |

Page 1 of 6. [Older](/companies/ccel/filings.md?page=2)
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 24, 2026, 14:58 ET. No prices; not investment advice.